Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results
Kutumbetov L. Myrzakhmetova B. Tussipova A. Zhapparova G. Tlenchiyeva T. Bissenbayeva K. Zhapar K. Zhugunissov K. Nurabayev S. Kerimbayev A.
December 2024Multidisciplinary Digital Publishing Institute (MDPI)
Vaccines
2024#12Issue 12
The research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine, developed by attenuating SARS-CoV-2 via numerous Vero cell passages, had no significant adverse effects in acute and subacute toxicity assessments, even at elevated dosages. Allergenicity testing indicated the absence of both immediate and delayed hypersensitivity reactions. Immunogenicity evaluations revealed strong virus-neutralizing antibody responses, especially following intranasal and intratracheal delivery. Studies on reversibility and transmission further validated the vaccine’s stability and non-pathogenicity. The data indicate that QazCovid-live is safe, immunogenic, and prepared for clinical trials, presenting a potential strategy for COVID-19 prevention.
COVID-19 prevention , live attenuated vaccine , preclinical study , QazCOVID-live , SARS-CoV-2 , vaccine safety , virus attenuation , virus-neutralizing antibodies
Text of the article Перейти на текст статьи
Research Institute for Biological Safety Problems, Gvardeiskiy, 080409, Kazakhstan
Research Institute for Biological Safety Problems
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026